AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
RenovoRx, Inc.
Video analysis: RNXT
All videosNo video analysis for this stock yet. Request one from our team.
News: RNXT
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C.
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the journal Cancer Chemotherapy and Pharmacology.
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company's Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTrading.
RenovoRx Q2 Earnings Call Highlights
RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.
Similar companies
-
Elutia Inc
ELUT
·
NASDAQ
Compare
-
Lantern Pharma Inc.
LTRN
·
NASDAQ
Compare
-
Reviva Pharmaceuticals Holdings, Inc.
RVPH
·
Other OTC
Compare
-
MAIA Biotechnology, Inc.
MAIA
·
New York Stock Exchange Arca
Compare
-
Annovis Bio, Inc.
ANVS
·
New York Stock Exchange
Compare
-
Tvardi Therapeutics, Inc.
TVRD
·
NASDAQ
Compare